ASH 2016

Area: Hematology

Location: San Diego, United States

Date: December 3 to December 6

Description:

American Society of Hematology.


Search in Scientific Content:
Date
Filters:
ErythroMer
4:26

ErythroMer - Nanoscale Bio-Synthetic Artificial Red Cell

Presenter: Allan Doctor
Hematology
Leveraging
6:41

Leveraging the Contractile Force of Platelets for Targeted Factor VIII Delivery in Hemophilia with Inhibitors

Presenter: Caroline E. Hansen
Hematology
Survival F
6:02

Survival Following Allogeneic Hematopoietic Cell Transplantation in High-Risk AML Patients Initially Treated with CPX-351 vs. Standard Cytarabine and Daunorubi

Presenter: Jeffrey E. Lancet
Hematology
Minimal Re
6:57

Minimal Residual Disease Negative Complete Remissions Following Anti-CD22 CAR in Children and Young Adults with Relapsed/Refractory ALL

Presenter: Terry J Fry
Hematology
SUSTAIN St
10:28

SUSTAIN Study: Assessing Safety and Efficacy of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises

Presenter: Kenneth I. Ataga
Hematology
Feasibilit
9:05

Feasibility Trial for Primary Stroke Prevention in Children with Sickle Cell Anemia in Nigeria (SPIN Trial)

Presenter: Najibah Aliyu Galadanci
Hematology
Prospectiv
5:32

Prospective Implementation of Multi-Disciplinary Obstetric Team Decreases the Mortality Rate of Pregnant Women with Sickle Cell Disease in Ghana

Presenter: Eugenia Vicky Asare
Hematology
Determinin
5:19

Determining the Incidence and Risk Factors for Central Venous Catheter Related Thrombosis in Children

Presenter: Julie Jaffray
Hematology
A Phase 1b
12:08

A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy for Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Presenter: Harry P. Erba
Hematology
Cessation
6:30

Cessation of Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients with Deep Molecular Response: Results of the Euro-Ski Trial

Presenter: Francois-Xavier Mahon
Hematology
Chronic My
5:39

Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study

Presenter: Mhairi Copland
Hematology
A Miniatur
5:30

A Miniaturized Microfluidic Dielectric Sensor for Point-of-Care Assessment of Blood Coagulation

Presenter: Evi X. Stavrou
Hematology
Quality of
14:02

Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Presenter: Francois-Xavier Mahon
Hematology
Overcoming
4:13

Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells

Presenter: Marco Ruella
Hematology
Novelties
2:56

Novelties and future directions in AML therapy

Presenter: Farhad Ravandi
Hematology
Chronic my
4:22

Chronic myeloid leukemia: First-line drug of choice; TKIs

Presenter: Elias Jabbour
Hematology
Influencin
3:58

Influencing B-cell Receptor Signaling; Results from studies with ibrutinib (PCYC-1102, 1103, RESONATE-2 Trial)

Presenter: Jeffrey Jones
Hematology
Summary of
7:21

Summary of venetoclax therapy in CLL

Presenter: Jeffrey Jones
Hematology
Patient-Re
6:31

Patient-Reported Quality of Life before and after Stopping Treatment in the ENESTop Trial of Treatment-Free Remission for Patients with Chronic Myeloid Leukemia in Chronic Phase

Presenter: Jeffrey H. Lipton
Hematology
Single-Age
4:05

Single-Agent Ibrutinib Demonstrates Efficacy and Safety in Patients with Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter, Open-Label, Phase 2 Study

Presenter: Ariele Noy
Hematology
Long-Term
4:59

Long-Term Follow-up of Patients with Corticosteroid-Refractory Graft-Versus-Host Disease Treated with Ruxolitinib

Presenter: Robert Zeiser
Hematology
COMFORT-I
2:45

COMFORT-I Study: Effects of Long-Term Ruxolitinib on Bone Marrow Morphology in Patients with Myelofibrosis

Presenter: Hans Michael Kvasnicka
Hematology
Subgroup A
7:39

Subgroup Analysis from ENESTop: Treatment-Free Remission in Patients with CML in Chronic Phase According to Reasons for Switching from Imatinib to Nilotini

Presenter: Timothy P. Hughes
Hematology
GALLIUM St
7:47

GALLIUM Study: Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance

Presenter: Christiane Pott
Hematology
Treatment
3:21

Treatment options of CLL

Presenter: John F. Seymour
Hematology
Institute/
8:11

Institute/Carolinas HealthCare System, Charlotte, US, Study results with daratumumab

Presenter: Saad Z. Usmani
Hematology
Pooled OS
4:39

Pooled OS Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials

Presenter: Srdan Verstovsek
Hematology
New therap
4:06

New therapeutic approaches in CLL, special focus on venetoclax

Presenter: Matthew S. Davids
Hematology

ASH 2018

2018-12-01 - 2018-12-04
San Diego, United States

EHA 2018

2018-06-14 - 2018-06-17
Stockholm, Sweden

ASH 2017

2017-12-09 - 2017-12-12
Atlanta, United States

EHA 2017

2017-06-22 - 2017-06-25
Madrid, Spain

ICML 2017

2017-06-14 - 2017-06-17
Lugano, Switzerland

ASH 2015

2015-12-05 - 2015-12-08
Orlando, United States

EHA 2015

2015-06-11 - 2015-06-14
Vienna, Australia